{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T14:30:17Z","timestamp":1789223417257,"version":"build-2803163510"},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.diagmicrobio.2021.115484","type":"journal-article","created":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T00:34:47Z","timestamp":1625877287000},"page":"115484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Analysis of antimicrobial susceptibility testing methods and variables and in vitro activity of gepotidacin against urogenital Neisseria gonorrhoeae in men"],"prefix":"10.1016","volume":"101","author":[{"given":"Nicole E.","family":"Scangarella-Oman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Koeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanna","family":"DiFranco-Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda A.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2021.115484_bib0001","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nature09197","article-title":"Type IIA topoisomerase inhibition by a new class of antibacterial agents","volume":"466","author":"Bax","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.diagmicrobio.2021.115484_bib0002","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1128\/AAC.02820-15","article-title":"In vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens","volume":"60","author":"Biedenbach","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115484_bib0003","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/jac\/dku396","article-title":"Stemming the tide of drug-resistant Neisseria gonorrhoeae: the need for an individualized approach to treatment","volume":"70","author":"Buono","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115484_bib0004","unstructured":"Centers for Disease Control and Prevention (CDC). Gonococcal isolate surveillance project protoco l. 2016. Available at: https:\/\/www.cdc.gov\/std\/gisp\/gisp-protocol-may-2016.pdf. Accessed January 28, 2021."},{"key":"10.1016\/j.diagmicrobio.2021.115484_bib0005","series-title":"M07-A10 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","first-page":"87","year":"2015"},{"key":"10.1016\/j.diagmicrobio.2021.115484_bib0006","series-title":"M100 perfomance standards for antimicrobial susceptibility testing","first-page":"293","year":"2020"},{"key":"10.1016\/j.diagmicrobio.2021.115484_bib0007","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bjm.2017.06.001","article-title":"Antimicrobial resistance in Neisseria gonorrhoeae: history, molecular mechanisms and epidemiological aspects of an emerging global threat","volume":"48","author":"Costa-Lourenco","year":"2017","journal-title":"Braz J Microbiol"},{"key":"10.1016\/j.diagmicrobio.2021.115484_bib0008","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02047-16","article-title":"In vitro activity of gepotidacin (GSK2140944) against Neisseria gonorrhoeae","volume":"61","author":"Farrell","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115484_bib0009","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1021\/acsinfecdis.8b00315","article-title":"Mechanistic and structural basis for the actions of the antibacterial gepotidacin against staphylococcus aureus gyrase","volume":"5","author":"Gibson","year":"2019","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2021.115484_bib0010","doi-asserted-by":"crossref","first-page":"371","DOI":"10.15698\/mic2016.09.524","article-title":"Gonorrhea - an evolving disease of the new millennium","volume":"3","author":"Hill","year":"2016","journal-title":"Microb Cell"},{"key":"10.1016\/j.diagmicrobio.2021.115484_bib0011","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1093\/jac\/dky162","article-title":"In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR Neisseria gonorrhoeae","volume":"73","author":"Jacobsson","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115484_bib0012","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1128\/JCM.02366-16","article-title":"Analysis of MIC and disk diffusion testing variables for gepotidacin and comparator agents against select bacterial pathogens","volume":"55","author":"Koeth","year":"2017","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2021.115484_bib0013","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02095-16","article-title":"Efficacy, safety, and tolerability of gepotidacin (GSK2140944) in the treatment of patients with suspected or confirmed gram-positive acute bacterial skin and skin structure infections","volume":"61","author":"O'Riordan","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115484_bib0014","doi-asserted-by":"crossref","DOI":"10.2471\/BLT.18.228486","article-title":"Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates","volume":"97","author":"Rowley","year":"2019","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.diagmicrobio.2021.115484_bib0015","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01221-18","article-title":"Microbiological analysis from a phase 2 Randomized Study in adults evaluating single oral doses of gepotidacin in the treatment of uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae","volume":"62","author":"Scangarella-Oman","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115484_bib0016","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/cid\/ciy145","article-title":"2018. Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: a phase 2, randomized, dose-ranging, single-oral dose evaluation","volume":"67","author":"Taylor","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2021.115484_bib0017","series-title":"Enter for devices and radiological health guidance for industry and FDA","year":"2009"},{"key":"10.1016\/j.diagmicrobio.2021.115484_bib0018","series-title":"WHO Guidelines for the treatment of Neisseria gonorrhoeae","first-page":"55","year":"2016"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889321001772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889321001772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:56:08Z","timestamp":1760003768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889321001772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0732889321001772"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2021.115484","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of antimicrobial susceptibility testing methods and variables and in vitro activity of gepotidacin against urogenital Neisseria gonorrhoeae in men","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2021.115484","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 GlaxoSmithKline plc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115484"}}